nodes	percent_of_prediction	percent_of_DWPC	metapath
Remifentanil—Alfentanil—CYP3A5—prostate cancer	0.00406	0.342	CrCbGaD
Remifentanil—Sufentanil—CYP3A4—prostate cancer	0.00189	0.159	CrCbGaD
Remifentanil—Alfentanil—CYP3A4—prostate cancer	0.00176	0.148	CrCbGaD
Remifentanil—Fentanyl—CYP3A5—prostate cancer	0.00149	0.125	CrCbGaD
Remifentanil—Pethidine—CYP2C19—prostate cancer	0.00125	0.105	CrCbGaD
Remifentanil—Pethidine—CYP3A4—prostate cancer	0.000792	0.0667	CrCbGaD
Remifentanil—Fentanyl—CYP3A4—prostate cancer	0.000643	0.0542	CrCbGaD
Remifentanil—Dysphagia—Doxorubicin—prostate cancer	0.000378	0.000452	CcSEcCtD
Remifentanil—Anaemia—Capecitabine—prostate cancer	0.000377	0.000451	CcSEcCtD
Remifentanil—Immune system disorder—Prednisone—prostate cancer	0.000377	0.000451	CcSEcCtD
Remifentanil—Arrhythmia—Prednisone—prostate cancer	0.000373	0.000446	CcSEcCtD
Remifentanil—Paraesthesia—Etoposide—prostate cancer	0.000372	0.000445	CcSEcCtD
Remifentanil—Loss of consciousness—Docetaxel—prostate cancer	0.000371	0.000443	CcSEcCtD
Remifentanil—Dyspnoea—Etoposide—prostate cancer	0.000369	0.000442	CcSEcCtD
Remifentanil—Hyperglycaemia—Epirubicin—prostate cancer	0.000368	0.00044	CcSEcCtD
Remifentanil—Somnolence—Etoposide—prostate cancer	0.000368	0.00044	CcSEcCtD
Remifentanil—Cough—Docetaxel—prostate cancer	0.000368	0.00044	CcSEcCtD
Remifentanil—Hypersensitivity—Mitoxantrone—prostate cancer	0.000367	0.000439	CcSEcCtD
Remifentanil—Syncope—Capecitabine—prostate cancer	0.000366	0.000438	CcSEcCtD
Remifentanil—Pneumonia—Epirubicin—prostate cancer	0.000366	0.000438	CcSEcCtD
Remifentanil—Diarrhoea—Estradiol—prostate cancer	0.000366	0.000437	CcSEcCtD
Remifentanil—Convulsion—Docetaxel—prostate cancer	0.000365	0.000437	CcSEcCtD
Remifentanil—Hypertension—Docetaxel—prostate cancer	0.000364	0.000435	CcSEcCtD
Remifentanil—Erythema—Prednisone—prostate cancer	0.000364	0.000435	CcSEcCtD
Remifentanil—Bronchitis—Doxorubicin—prostate cancer	0.000363	0.000435	CcSEcCtD
Remifentanil—Loss of consciousness—Capecitabine—prostate cancer	0.000359	0.000429	CcSEcCtD
Remifentanil—Renal failure—Epirubicin—prostate cancer	0.000358	0.000428	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Etoposide—prostate cancer	0.000357	0.000428	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000356	0.000426	CcSEcCtD
Remifentanil—Cough—Capecitabine—prostate cancer	0.000356	0.000426	CcSEcCtD
Remifentanil—Constipation—Etoposide—prostate cancer	0.000354	0.000424	CcSEcCtD
Remifentanil—Pain—Etoposide—prostate cancer	0.000354	0.000424	CcSEcCtD
Remifentanil—Dizziness—Estradiol—prostate cancer	0.000353	0.000423	CcSEcCtD
Remifentanil—Dysuria—Doxorubicin—prostate cancer	0.000353	0.000422	CcSEcCtD
Remifentanil—Hypertension—Capecitabine—prostate cancer	0.000352	0.000422	CcSEcCtD
Remifentanil—Dry mouth—Docetaxel—prostate cancer	0.000351	0.00042	CcSEcCtD
Remifentanil—Sweating—Epirubicin—prostate cancer	0.000349	0.000417	CcSEcCtD
Remifentanil—Haematuria—Epirubicin—prostate cancer	0.000347	0.000415	CcSEcCtD
Remifentanil—Confusional state—Docetaxel—prostate cancer	0.000347	0.000415	CcSEcCtD
Remifentanil—Anxiety—Capecitabine—prostate cancer	0.000346	0.000414	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000345	0.000413	CcSEcCtD
Remifentanil—Oedema—Docetaxel—prostate cancer	0.000344	0.000412	CcSEcCtD
Remifentanil—Anaphylactic shock—Docetaxel—prostate cancer	0.000344	0.000412	CcSEcCtD
Remifentanil—Feeling abnormal—Etoposide—prostate cancer	0.000341	0.000408	CcSEcCtD
Remifentanil—Hyperglycaemia—Doxorubicin—prostate cancer	0.000341	0.000408	CcSEcCtD
Remifentanil—Diarrhoea—Mitoxantrone—prostate cancer	0.000341	0.000407	CcSEcCtD
Remifentanil—Dry mouth—Capecitabine—prostate cancer	0.00034	0.000407	CcSEcCtD
Remifentanil—Vomiting—Estradiol—prostate cancer	0.00034	0.000406	CcSEcCtD
Remifentanil—Pneumonia—Doxorubicin—prostate cancer	0.000339	0.000405	CcSEcCtD
Remifentanil—Shock—Docetaxel—prostate cancer	0.000339	0.000405	CcSEcCtD
Remifentanil—Nervous system disorder—Docetaxel—prostate cancer	0.000337	0.000404	CcSEcCtD
Remifentanil—Thrombocytopenia—Docetaxel—prostate cancer	0.000337	0.000403	CcSEcCtD
Remifentanil—Rash—Estradiol—prostate cancer	0.000337	0.000403	CcSEcCtD
Remifentanil—Dermatitis—Estradiol—prostate cancer	0.000337	0.000403	CcSEcCtD
Remifentanil—Anaemia—Prednisone—prostate cancer	0.000336	0.000402	CcSEcCtD
Remifentanil—Confusional state—Capecitabine—prostate cancer	0.000336	0.000402	CcSEcCtD
Remifentanil—Tachycardia—Docetaxel—prostate cancer	0.000336	0.000402	CcSEcCtD
Remifentanil—Headache—Estradiol—prostate cancer	0.000335	0.0004	CcSEcCtD
Remifentanil—Skin disorder—Docetaxel—prostate cancer	0.000334	0.0004	CcSEcCtD
Remifentanil—Agitation—Prednisone—prostate cancer	0.000334	0.0004	CcSEcCtD
Remifentanil—Oedema—Capecitabine—prostate cancer	0.000333	0.000399	CcSEcCtD
Remifentanil—Bradycardia—Epirubicin—prostate cancer	0.000333	0.000398	CcSEcCtD
Remifentanil—Renal failure—Doxorubicin—prostate cancer	0.000331	0.000396	CcSEcCtD
Remifentanil—Urticaria—Etoposide—prostate cancer	0.000329	0.000394	CcSEcCtD
Remifentanil—Haemoglobin—Epirubicin—prostate cancer	0.000328	0.000393	CcSEcCtD
Remifentanil—Shock—Capecitabine—prostate cancer	0.000328	0.000392	CcSEcCtD
Remifentanil—Body temperature increased—Etoposide—prostate cancer	0.000327	0.000392	CcSEcCtD
Remifentanil—Nervous system disorder—Capecitabine—prostate cancer	0.000327	0.000391	CcSEcCtD
Remifentanil—Haemorrhage—Epirubicin—prostate cancer	0.000327	0.000391	CcSEcCtD
Remifentanil—Thrombocytopenia—Capecitabine—prostate cancer	0.000326	0.00039	CcSEcCtD
Remifentanil—Syncope—Prednisone—prostate cancer	0.000326	0.00039	CcSEcCtD
Remifentanil—Tachycardia—Capecitabine—prostate cancer	0.000325	0.000389	CcSEcCtD
Remifentanil—Pharyngitis—Epirubicin—prostate cancer	0.000324	0.000388	CcSEcCtD
Remifentanil—Skin disorder—Capecitabine—prostate cancer	0.000324	0.000387	CcSEcCtD
Remifentanil—Sweating—Doxorubicin—prostate cancer	0.000323	0.000386	CcSEcCtD
Remifentanil—Hyperhidrosis—Capecitabine—prostate cancer	0.000322	0.000385	CcSEcCtD
Remifentanil—Hypotension—Docetaxel—prostate cancer	0.000322	0.000385	CcSEcCtD
Remifentanil—Haematuria—Doxorubicin—prostate cancer	0.000321	0.000384	CcSEcCtD
Remifentanil—Loss of consciousness—Prednisone—prostate cancer	0.00032	0.000382	CcSEcCtD
Remifentanil—Nausea—Estradiol—prostate cancer	0.000317	0.00038	CcSEcCtD
Remifentanil—Vomiting—Mitoxantrone—prostate cancer	0.000316	0.000379	CcSEcCtD
Remifentanil—Convulsion—Prednisone—prostate cancer	0.000315	0.000377	CcSEcCtD
Remifentanil—Visual impairment—Epirubicin—prostate cancer	0.000315	0.000377	CcSEcCtD
Remifentanil—Hypertension—Prednisone—prostate cancer	0.000314	0.000376	CcSEcCtD
Remifentanil—Rash—Mitoxantrone—prostate cancer	0.000314	0.000375	CcSEcCtD
Remifentanil—Dermatitis—Mitoxantrone—prostate cancer	0.000314	0.000375	CcSEcCtD
Remifentanil—Headache—Mitoxantrone—prostate cancer	0.000312	0.000373	CcSEcCtD
Remifentanil—Hypotension—Capecitabine—prostate cancer	0.000311	0.000372	CcSEcCtD
Remifentanil—Paraesthesia—Docetaxel—prostate cancer	0.000309	0.00037	CcSEcCtD
Remifentanil—Anxiety—Prednisone—prostate cancer	0.000308	0.000369	CcSEcCtD
Remifentanil—Bradycardia—Doxorubicin—prostate cancer	0.000308	0.000368	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000307	0.000368	CcSEcCtD
Remifentanil—Dyspnoea—Docetaxel—prostate cancer	0.000307	0.000367	CcSEcCtD
Remifentanil—Somnolence—Docetaxel—prostate cancer	0.000306	0.000366	CcSEcCtD
Remifentanil—Hypersensitivity—Etoposide—prostate cancer	0.000305	0.000365	CcSEcCtD
Remifentanil—Haemoglobin—Doxorubicin—prostate cancer	0.000304	0.000363	CcSEcCtD
Remifentanil—Flushing—Epirubicin—prostate cancer	0.000303	0.000363	CcSEcCtD
Remifentanil—Cardiac disorder—Epirubicin—prostate cancer	0.000303	0.000363	CcSEcCtD
Remifentanil—Dyspepsia—Docetaxel—prostate cancer	0.000303	0.000362	CcSEcCtD
Remifentanil—Haemorrhage—Doxorubicin—prostate cancer	0.000302	0.000362	CcSEcCtD
Remifentanil—Pharyngitis—Doxorubicin—prostate cancer	0.0003	0.000359	CcSEcCtD
Remifentanil—Paraesthesia—Capecitabine—prostate cancer	0.000299	0.000358	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000297	0.000355	CcSEcCtD
Remifentanil—Dyspnoea—Capecitabine—prostate cancer	0.000297	0.000355	CcSEcCtD
Remifentanil—Oedema—Prednisone—prostate cancer	0.000297	0.000355	CcSEcCtD
Remifentanil—Anaphylactic shock—Prednisone—prostate cancer	0.000297	0.000355	CcSEcCtD
Remifentanil—Angiopathy—Epirubicin—prostate cancer	0.000296	0.000355	CcSEcCtD
Remifentanil—Nausea—Mitoxantrone—prostate cancer	0.000296	0.000354	CcSEcCtD
Remifentanil—Immune system disorder—Epirubicin—prostate cancer	0.000295	0.000353	CcSEcCtD
Remifentanil—Mediastinal disorder—Epirubicin—prostate cancer	0.000294	0.000352	CcSEcCtD
Remifentanil—Constipation—Docetaxel—prostate cancer	0.000294	0.000352	CcSEcCtD
Remifentanil—Pain—Docetaxel—prostate cancer	0.000294	0.000352	CcSEcCtD
Remifentanil—Dyspepsia—Capecitabine—prostate cancer	0.000293	0.000351	CcSEcCtD
Remifentanil—Chills—Epirubicin—prostate cancer	0.000293	0.000351	CcSEcCtD
Remifentanil—Pruritus—Etoposide—prostate cancer	0.000293	0.00035	CcSEcCtD
Remifentanil—Shock—Prednisone—prostate cancer	0.000292	0.000349	CcSEcCtD
Remifentanil—Arrhythmia—Epirubicin—prostate cancer	0.000292	0.000349	CcSEcCtD
Remifentanil—Visual impairment—Doxorubicin—prostate cancer	0.000291	0.000348	CcSEcCtD
Remifentanil—Nervous system disorder—Prednisone—prostate cancer	0.000291	0.000348	CcSEcCtD
Remifentanil—Tachycardia—Prednisone—prostate cancer	0.00029	0.000347	CcSEcCtD
Remifentanil—Skin disorder—Prednisone—prostate cancer	0.000288	0.000345	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000288	0.000344	CcSEcCtD
Remifentanil—Hyperhidrosis—Prednisone—prostate cancer	0.000287	0.000343	CcSEcCtD
Remifentanil—Constipation—Capecitabine—prostate cancer	0.000285	0.000341	CcSEcCtD
Remifentanil—Pain—Capecitabine—prostate cancer	0.000285	0.000341	CcSEcCtD
Remifentanil—Erythema—Epirubicin—prostate cancer	0.000284	0.00034	CcSEcCtD
Remifentanil—Feeling abnormal—Docetaxel—prostate cancer	0.000284	0.000339	CcSEcCtD
Remifentanil—Diarrhoea—Etoposide—prostate cancer	0.000283	0.000339	CcSEcCtD
Remifentanil—Flushing—Doxorubicin—prostate cancer	0.000281	0.000336	CcSEcCtD
Remifentanil—Cardiac disorder—Doxorubicin—prostate cancer	0.000281	0.000336	CcSEcCtD
Remifentanil—Feeling abnormal—Capecitabine—prostate cancer	0.000275	0.000328	CcSEcCtD
Remifentanil—Angiopathy—Doxorubicin—prostate cancer	0.000274	0.000328	CcSEcCtD
Remifentanil—Dizziness—Etoposide—prostate cancer	0.000274	0.000328	CcSEcCtD
Remifentanil—Immune system disorder—Doxorubicin—prostate cancer	0.000273	0.000327	CcSEcCtD
Remifentanil—Mediastinal disorder—Doxorubicin—prostate cancer	0.000272	0.000326	CcSEcCtD
Remifentanil—Body temperature increased—Docetaxel—prostate cancer	0.000272	0.000325	CcSEcCtD
Remifentanil—Chills—Doxorubicin—prostate cancer	0.000271	0.000324	CcSEcCtD
Remifentanil—Arrhythmia—Doxorubicin—prostate cancer	0.00027	0.000323	CcSEcCtD
Remifentanil—Paraesthesia—Prednisone—prostate cancer	0.000266	0.000319	CcSEcCtD
Remifentanil—Urticaria—Capecitabine—prostate cancer	0.000265	0.000317	CcSEcCtD
Remifentanil—Body temperature increased—Capecitabine—prostate cancer	0.000263	0.000315	CcSEcCtD
Remifentanil—Vomiting—Etoposide—prostate cancer	0.000263	0.000315	CcSEcCtD
Remifentanil—Erythema—Doxorubicin—prostate cancer	0.000263	0.000315	CcSEcCtD
Remifentanil—Anaemia—Epirubicin—prostate cancer	0.000263	0.000314	CcSEcCtD
Remifentanil—Agitation—Epirubicin—prostate cancer	0.000261	0.000313	CcSEcCtD
Remifentanil—Dyspepsia—Prednisone—prostate cancer	0.000261	0.000313	CcSEcCtD
Remifentanil—Rash—Etoposide—prostate cancer	0.000261	0.000312	CcSEcCtD
Remifentanil—Dermatitis—Etoposide—prostate cancer	0.000261	0.000312	CcSEcCtD
Remifentanil—Headache—Etoposide—prostate cancer	0.000259	0.00031	CcSEcCtD
Remifentanil—Syncope—Epirubicin—prostate cancer	0.000255	0.000305	CcSEcCtD
Remifentanil—Constipation—Prednisone—prostate cancer	0.000254	0.000304	CcSEcCtD
Remifentanil—Hypersensitivity—Docetaxel—prostate cancer	0.000254	0.000303	CcSEcCtD
Remifentanil—Loss of consciousness—Epirubicin—prostate cancer	0.00025	0.000299	CcSEcCtD
Remifentanil—Cough—Epirubicin—prostate cancer	0.000248	0.000297	CcSEcCtD
Remifentanil—Convulsion—Epirubicin—prostate cancer	0.000246	0.000295	CcSEcCtD
Remifentanil—Nausea—Etoposide—prostate cancer	0.000246	0.000294	CcSEcCtD
Remifentanil—Hypertension—Epirubicin—prostate cancer	0.000246	0.000294	CcSEcCtD
Remifentanil—Hypersensitivity—Capecitabine—prostate cancer	0.000245	0.000294	CcSEcCtD
Remifentanil—Feeling abnormal—Prednisone—prostate cancer	0.000245	0.000293	CcSEcCtD
Remifentanil—Pruritus—Docetaxel—prostate cancer	0.000243	0.000291	CcSEcCtD
Remifentanil—Anaemia—Doxorubicin—prostate cancer	0.000243	0.000291	CcSEcCtD
Remifentanil—Agitation—Doxorubicin—prostate cancer	0.000242	0.000289	CcSEcCtD
Remifentanil—Anxiety—Epirubicin—prostate cancer	0.000241	0.000289	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.00024	0.000288	CcSEcCtD
Remifentanil—Dry mouth—Epirubicin—prostate cancer	0.000237	0.000283	CcSEcCtD
Remifentanil—Syncope—Doxorubicin—prostate cancer	0.000236	0.000282	CcSEcCtD
Remifentanil—Urticaria—Prednisone—prostate cancer	0.000236	0.000282	CcSEcCtD
Remifentanil—Pruritus—Capecitabine—prostate cancer	0.000236	0.000282	CcSEcCtD
Remifentanil—Diarrhoea—Docetaxel—prostate cancer	0.000235	0.000282	CcSEcCtD
Remifentanil—Body temperature increased—Prednisone—prostate cancer	0.000235	0.000281	CcSEcCtD
Remifentanil—Confusional state—Epirubicin—prostate cancer	0.000234	0.00028	CcSEcCtD
Remifentanil—Anaphylactic shock—Epirubicin—prostate cancer	0.000232	0.000278	CcSEcCtD
Remifentanil—Oedema—Epirubicin—prostate cancer	0.000232	0.000278	CcSEcCtD
Remifentanil—Loss of consciousness—Doxorubicin—prostate cancer	0.000231	0.000277	CcSEcCtD
Remifentanil—Cough—Doxorubicin—prostate cancer	0.00023	0.000275	CcSEcCtD
Remifentanil—Shock—Epirubicin—prostate cancer	0.000228	0.000273	CcSEcCtD
Remifentanil—Convulsion—Doxorubicin—prostate cancer	0.000228	0.000273	CcSEcCtD
Remifentanil—Diarrhoea—Capecitabine—prostate cancer	0.000228	0.000273	CcSEcCtD
Remifentanil—Nervous system disorder—Epirubicin—prostate cancer	0.000228	0.000272	CcSEcCtD
Remifentanil—Dizziness—Docetaxel—prostate cancer	0.000228	0.000272	CcSEcCtD
Remifentanil—Thrombocytopenia—Epirubicin—prostate cancer	0.000227	0.000272	CcSEcCtD
Remifentanil—Hypertension—Doxorubicin—prostate cancer	0.000227	0.000272	CcSEcCtD
Remifentanil—Tachycardia—Epirubicin—prostate cancer	0.000227	0.000271	CcSEcCtD
Remifentanil—Skin disorder—Epirubicin—prostate cancer	0.000225	0.00027	CcSEcCtD
Remifentanil—Hyperhidrosis—Epirubicin—prostate cancer	0.000224	0.000268	CcSEcCtD
Remifentanil—Anxiety—Doxorubicin—prostate cancer	0.000223	0.000267	CcSEcCtD
Remifentanil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000222	0.000266	CcSEcCtD
Remifentanil—Dizziness—Capecitabine—prostate cancer	0.00022	0.000264	CcSEcCtD
Remifentanil—Dry mouth—Doxorubicin—prostate cancer	0.000219	0.000262	CcSEcCtD
Remifentanil—Vomiting—Docetaxel—prostate cancer	0.000219	0.000262	CcSEcCtD
Remifentanil—Hypersensitivity—Prednisone—prostate cancer	0.000219	0.000262	CcSEcCtD
Remifentanil—Rash—Docetaxel—prostate cancer	0.000217	0.00026	CcSEcCtD
Remifentanil—Hypotension—Epirubicin—prostate cancer	0.000217	0.000259	CcSEcCtD
Remifentanil—Dermatitis—Docetaxel—prostate cancer	0.000217	0.000259	CcSEcCtD
Remifentanil—Confusional state—Doxorubicin—prostate cancer	0.000217	0.000259	CcSEcCtD
Remifentanil—Headache—Docetaxel—prostate cancer	0.000216	0.000258	CcSEcCtD
Remifentanil—Oedema—Doxorubicin—prostate cancer	0.000215	0.000257	CcSEcCtD
Remifentanil—Anaphylactic shock—Doxorubicin—prostate cancer	0.000215	0.000257	CcSEcCtD
Remifentanil—Vomiting—Capecitabine—prostate cancer	0.000212	0.000253	CcSEcCtD
Remifentanil—Shock—Doxorubicin—prostate cancer	0.000211	0.000253	CcSEcCtD
Remifentanil—Nervous system disorder—Doxorubicin—prostate cancer	0.000211	0.000252	CcSEcCtD
Remifentanil—Thrombocytopenia—Doxorubicin—prostate cancer	0.00021	0.000252	CcSEcCtD
Remifentanil—Rash—Capecitabine—prostate cancer	0.00021	0.000251	CcSEcCtD
Remifentanil—Pruritus—Prednisone—prostate cancer	0.00021	0.000251	CcSEcCtD
Remifentanil—Dermatitis—Capecitabine—prostate cancer	0.00021	0.000251	CcSEcCtD
Remifentanil—Tachycardia—Doxorubicin—prostate cancer	0.00021	0.000251	CcSEcCtD
Remifentanil—Headache—Capecitabine—prostate cancer	0.000209	0.00025	CcSEcCtD
Remifentanil—Skin disorder—Doxorubicin—prostate cancer	0.000209	0.00025	CcSEcCtD
Remifentanil—Paraesthesia—Epirubicin—prostate cancer	0.000208	0.000249	CcSEcCtD
Remifentanil—Hyperhidrosis—Doxorubicin—prostate cancer	0.000208	0.000248	CcSEcCtD
Remifentanil—Dyspnoea—Epirubicin—prostate cancer	0.000207	0.000248	CcSEcCtD
Remifentanil—Somnolence—Epirubicin—prostate cancer	0.000206	0.000247	CcSEcCtD
Remifentanil—Nausea—Docetaxel—prostate cancer	0.000204	0.000245	CcSEcCtD
Remifentanil—Dyspepsia—Epirubicin—prostate cancer	0.000204	0.000244	CcSEcCtD
Remifentanil—Diarrhoea—Prednisone—prostate cancer	0.000203	0.000243	CcSEcCtD
Remifentanil—Hypotension—Doxorubicin—prostate cancer	0.000201	0.00024	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Epirubicin—prostate cancer	0.0002	0.00024	CcSEcCtD
Remifentanil—Constipation—Epirubicin—prostate cancer	0.000198	0.000237	CcSEcCtD
Remifentanil—Pain—Epirubicin—prostate cancer	0.000198	0.000237	CcSEcCtD
Remifentanil—Nausea—Capecitabine—prostate cancer	0.000198	0.000237	CcSEcCtD
Remifentanil—Dizziness—Prednisone—prostate cancer	0.000196	0.000235	CcSEcCtD
Remifentanil—Paraesthesia—Doxorubicin—prostate cancer	0.000193	0.000231	CcSEcCtD
Remifentanil—Dyspnoea—Doxorubicin—prostate cancer	0.000191	0.000229	CcSEcCtD
Remifentanil—Feeling abnormal—Epirubicin—prostate cancer	0.000191	0.000229	CcSEcCtD
Remifentanil—Somnolence—Doxorubicin—prostate cancer	0.000191	0.000228	CcSEcCtD
Remifentanil—Dyspepsia—Doxorubicin—prostate cancer	0.000189	0.000226	CcSEcCtD
Remifentanil—Vomiting—Prednisone—prostate cancer	0.000189	0.000226	CcSEcCtD
Remifentanil—Rash—Prednisone—prostate cancer	0.000187	0.000224	CcSEcCtD
Remifentanil—Dermatitis—Prednisone—prostate cancer	0.000187	0.000224	CcSEcCtD
Remifentanil—Headache—Prednisone—prostate cancer	0.000186	0.000222	CcSEcCtD
Remifentanil—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000185	0.000222	CcSEcCtD
Remifentanil—Urticaria—Epirubicin—prostate cancer	0.000184	0.000221	CcSEcCtD
Remifentanil—Pain—Doxorubicin—prostate cancer	0.000184	0.00022	CcSEcCtD
Remifentanil—Constipation—Doxorubicin—prostate cancer	0.000184	0.00022	CcSEcCtD
Remifentanil—Body temperature increased—Epirubicin—prostate cancer	0.000183	0.00022	CcSEcCtD
Remifentanil—Feeling abnormal—Doxorubicin—prostate cancer	0.000177	0.000212	CcSEcCtD
Remifentanil—Nausea—Prednisone—prostate cancer	0.000176	0.000211	CcSEcCtD
Remifentanil—Hypersensitivity—Epirubicin—prostate cancer	0.000171	0.000205	CcSEcCtD
Remifentanil—Urticaria—Doxorubicin—prostate cancer	0.000171	0.000204	CcSEcCtD
Remifentanil—Body temperature increased—Doxorubicin—prostate cancer	0.00017	0.000203	CcSEcCtD
Remifentanil—Pruritus—Epirubicin—prostate cancer	0.000164	0.000196	CcSEcCtD
Remifentanil—Diarrhoea—Epirubicin—prostate cancer	0.000159	0.00019	CcSEcCtD
Remifentanil—Hypersensitivity—Doxorubicin—prostate cancer	0.000158	0.000189	CcSEcCtD
Remifentanil—Dizziness—Epirubicin—prostate cancer	0.000153	0.000184	CcSEcCtD
Remifentanil—Pruritus—Doxorubicin—prostate cancer	0.000152	0.000182	CcSEcCtD
Remifentanil—Vomiting—Epirubicin—prostate cancer	0.000148	0.000177	CcSEcCtD
Remifentanil—Diarrhoea—Doxorubicin—prostate cancer	0.000147	0.000176	CcSEcCtD
Remifentanil—Rash—Epirubicin—prostate cancer	0.000146	0.000175	CcSEcCtD
Remifentanil—Dermatitis—Epirubicin—prostate cancer	0.000146	0.000175	CcSEcCtD
Remifentanil—Headache—Epirubicin—prostate cancer	0.000145	0.000174	CcSEcCtD
Remifentanil—Dizziness—Doxorubicin—prostate cancer	0.000142	0.00017	CcSEcCtD
Remifentanil—Nausea—Epirubicin—prostate cancer	0.000138	0.000165	CcSEcCtD
Remifentanil—Vomiting—Doxorubicin—prostate cancer	0.000137	0.000163	CcSEcCtD
Remifentanil—Rash—Doxorubicin—prostate cancer	0.000135	0.000162	CcSEcCtD
Remifentanil—Dermatitis—Doxorubicin—prostate cancer	0.000135	0.000162	CcSEcCtD
Remifentanil—Headache—Doxorubicin—prostate cancer	0.000135	0.000161	CcSEcCtD
Remifentanil—Nausea—Doxorubicin—prostate cancer	0.000128	0.000153	CcSEcCtD
Remifentanil—OPRD1—Signaling Pathways—PRKCQ—prostate cancer	6.75e-05	0.000443	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—FGFR4—prostate cancer	6.72e-05	0.000442	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PARP1—prostate cancer	6.72e-05	0.000442	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—MAP3K7—prostate cancer	6.67e-05	0.000438	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CALCA—prostate cancer	6.64e-05	0.000436	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CXCL12—prostate cancer	6.49e-05	0.000426	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—FGF10—prostate cancer	6.42e-05	0.000421	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TGFBR1—prostate cancer	6.38e-05	0.000419	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PTHLH—prostate cancer	6.38e-05	0.000419	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ADRB2—prostate cancer	6.35e-05	0.000417	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—AKR1C3—prostate cancer	6.27e-05	0.000412	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—JAK2—prostate cancer	6.26e-05	0.000411	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PRKACB—prostate cancer	6.24e-05	0.00041	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—MAP2K1—prostate cancer	6.24e-05	0.00041	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—PIK3CD—prostate cancer	6.2e-05	0.000407	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—VAV3—prostate cancer	6.19e-05	0.000407	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—PIK3CG—prostate cancer	6.18e-05	0.000406	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CASP9—prostate cancer	6.11e-05	0.000401	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—TGFBR2—prostate cancer	6.1e-05	0.000401	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PPP3CA—prostate cancer	6.08e-05	0.0004	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—THBS1—prostate cancer	6.08e-05	0.0004	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ITPR1—prostate cancer	6e-05	0.000394	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ANXA1—prostate cancer	6e-05	0.000394	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—PIK3CD—prostate cancer	5.98e-05	0.000393	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—PIK3CB—prostate cancer	5.95e-05	0.000391	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PRKCQ—prostate cancer	5.92e-05	0.000389	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—NGFR—prostate cancer	5.92e-05	0.000389	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PRKCZ—prostate cancer	5.88e-05	0.000386	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—MAP3K7—prostate cancer	5.85e-05	0.000384	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—PIK3CG—prostate cancer	5.75e-05	0.000378	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IGF1R—prostate cancer	5.74e-05	0.000377	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—CXCL8—prostate cancer	5.72e-05	0.000375	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—JAK2—prostate cancer	5.69e-05	0.000373	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—FGFR4—prostate cancer	5.68e-05	0.000373	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PARP1—prostate cancer	5.68e-05	0.000373	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—FGF10—prostate cancer	5.63e-05	0.000369	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CALCA—prostate cancer	5.61e-05	0.000369	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ADRB2—prostate cancer	5.57e-05	0.000366	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—LPL—prostate cancer	5.5e-05	0.000361	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—JAK2—prostate cancer	5.49e-05	0.000361	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CXCL12—prostate cancer	5.48e-05	0.00036	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—MAP2K1—prostate cancer	5.47e-05	0.000359	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—IL2—prostate cancer	5.46e-05	0.000359	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PDGFRB—prostate cancer	5.45e-05	0.000358	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—PIK3CD—prostate cancer	5.43e-05	0.000357	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—VAV3—prostate cancer	5.43e-05	0.000356	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—PIK3CB—prostate cancer	5.4e-05	0.000355	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—TGFBR2—prostate cancer	5.35e-05	0.000351	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ITGB3—prostate cancer	5.32e-05	0.000349	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ITPR1—prostate cancer	5.26e-05	0.000346	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—PIK3CG—prostate cancer	5.22e-05	0.000343	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—PIK3CB—prostate cancer	5.21e-05	0.000342	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—CXCL8—prostate cancer	5.19e-05	0.000341	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CASP9—prostate cancer	5.16e-05	0.000339	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ERBB3—prostate cancer	5.16e-05	0.000339	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—FGFR2—prostate cancer	5.15e-05	0.000338	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—PIK3CD—prostate cancer	5.06e-05	0.000332	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IGF1R—prostate cancer	5.03e-05	0.000331	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—CXCL8—prostate cancer	5.01e-05	0.000329	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—NGFR—prostate cancer	5e-05	0.000329	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PRKCQ—prostate cancer	5e-05	0.000329	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—JAK2—prostate cancer	4.99e-05	0.000327	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—IL2—prostate cancer	4.96e-05	0.000326	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—MAP3K7—prostate cancer	4.94e-05	0.000325	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—TERT—prostate cancer	4.94e-05	0.000325	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—LPL—prostate cancer	4.83e-05	0.000317	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—IL2—prostate cancer	4.79e-05	0.000315	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PDGFRB—prostate cancer	4.78e-05	0.000314	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—FGF10—prostate cancer	4.75e-05	0.000312	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—PIK3CB—prostate cancer	4.74e-05	0.000311	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—HIF1A—prostate cancer	4.73e-05	0.00031	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ADRB2—prostate cancer	4.7e-05	0.000309	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ITGB3—prostate cancer	4.66e-05	0.000306	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—JAK2—prostate cancer	4.64e-05	0.000305	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—MAP2K1—prostate cancer	4.62e-05	0.000304	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—LEP—prostate cancer	4.61e-05	0.000303	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—PIK3CD—prostate cancer	4.59e-05	0.000302	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—VAV3—prostate cancer	4.59e-05	0.000301	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CAV1—prostate cancer	4.57e-05	0.0003	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—CXCL8—prostate cancer	4.55e-05	0.000299	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TGFBR2—prostate cancer	4.52e-05	0.000297	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ERBB3—prostate cancer	4.52e-05	0.000297	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—KDR—prostate cancer	4.52e-05	0.000297	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—FGFR2—prostate cancer	4.51e-05	0.000296	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ITPR1—prostate cancer	4.45e-05	0.000292	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—PIK3CB—prostate cancer	4.41e-05	0.000289	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ESR1—prostate cancer	4.4e-05	0.000289	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—IL2—prostate cancer	4.35e-05	0.000286	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—TERT—prostate cancer	4.33e-05	0.000285	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—BAD—prostate cancer	4.3e-05	0.000282	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IGF1R—prostate cancer	4.25e-05	0.000279	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—CXCL8—prostate cancer	4.24e-05	0.000278	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—JAK2—prostate cancer	4.21e-05	0.000277	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—APC—prostate cancer	4.16e-05	0.000273	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PIK3CG—prostate cancer	4.16e-05	0.000273	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—HIF1A—prostate cancer	4.14e-05	0.000272	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—EGF—prostate cancer	4.12e-05	0.00027	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IRS1—prostate cancer	4.12e-05	0.00027	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—LPL—prostate cancer	4.08e-05	0.000268	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—IL2—prostate cancer	4.05e-05	0.000266	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—LEP—prostate cancer	4.05e-05	0.000266	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PDGFRB—prostate cancer	4.04e-05	0.000265	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CAV1—prostate cancer	4.01e-05	0.000263	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—PIK3CB—prostate cancer	4e-05	0.000263	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—GSK3B—prostate cancer	4e-05	0.000262	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—KDR—prostate cancer	3.96e-05	0.00026	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—INS—prostate cancer	3.94e-05	0.000259	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ITGB3—prostate cancer	3.94e-05	0.000259	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ESR1—prostate cancer	3.86e-05	0.000254	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CREBBP—prostate cancer	3.86e-05	0.000254	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—CXCL8—prostate cancer	3.85e-05	0.000253	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ERBB3—prostate cancer	3.82e-05	0.000251	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—FGFR2—prostate cancer	3.82e-05	0.000251	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IGF1—prostate cancer	3.81e-05	0.00025	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—EGFR—prostate cancer	3.79e-05	0.000249	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—BAD—prostate cancer	3.77e-05	0.000248	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—MAP2K1—prostate cancer	3.68e-05	0.000242	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—IL2—prostate cancer	3.68e-05	0.000241	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TERT—prostate cancer	3.66e-05	0.000241	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PIK3CD—prostate cancer	3.66e-05	0.00024	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PIK3CG—prostate cancer	3.65e-05	0.00024	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—APC—prostate cancer	3.65e-05	0.00024	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—PIK3CA—prostate cancer	3.63e-05	0.000238	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—SERPINE1—prostate cancer	3.62e-05	0.000238	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—EGF—prostate cancer	3.61e-05	0.000237	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IRS1—prostate cancer	3.61e-05	0.000237	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—KRAS—prostate cancer	3.58e-05	0.000235	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—FGF2—prostate cancer	3.5e-05	0.00023	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—GSK3B—prostate cancer	3.5e-05	0.00023	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—HIF1A—prostate cancer	3.5e-05	0.00023	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—NOS3—prostate cancer	3.46e-05	0.000227	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—INS—prostate cancer	3.46e-05	0.000227	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—LEP—prostate cancer	3.42e-05	0.000225	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CAV1—prostate cancer	3.39e-05	0.000222	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CREBBP—prostate cancer	3.39e-05	0.000222	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—JAK2—prostate cancer	3.36e-05	0.000221	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—KDR—prostate cancer	3.35e-05	0.00022	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IGF1—prostate cancer	3.34e-05	0.00022	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—EGFR—prostate cancer	3.33e-05	0.000218	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—PIK3CA—prostate cancer	3.29e-05	0.000216	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—MDM2—prostate cancer	3.28e-05	0.000215	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ESR1—prostate cancer	3.26e-05	0.000214	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—ERBB2—prostate cancer	3.23e-05	0.000212	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	3.23e-05	0.000212	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	3.21e-05	0.000211	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PIK3CB—prostate cancer	3.19e-05	0.00021	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—BAD—prostate cancer	3.19e-05	0.000209	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	3.18e-05	0.000209	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	3.17e-05	0.000208	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—KRAS—prostate cancer	3.14e-05	0.000206	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	3.09e-05	0.000203	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—APC—prostate cancer	3.09e-05	0.000203	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—FGF2—prostate cancer	3.07e-05	0.000202	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CXCL8—prostate cancer	3.07e-05	0.000201	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—EGF—prostate cancer	3.05e-05	0.0002	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IRS1—prostate cancer	3.05e-05	0.0002	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—NOS3—prostate cancer	3.03e-05	0.000199	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	2.99e-05	0.000197	CbGpPWpGaD
Remifentanil—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	2.96e-05	0.000195	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—GSK3B—prostate cancer	2.96e-05	0.000194	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—JAK2—prostate cancer	2.95e-05	0.000193	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CASP3—prostate cancer	2.93e-05	0.000193	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IL2—prostate cancer	2.93e-05	0.000192	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—INS—prostate cancer	2.92e-05	0.000192	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—IL6—prostate cancer	2.92e-05	0.000191	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	2.89e-05	0.00019	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—MDM2—prostate cancer	2.88e-05	0.000189	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CREBBP—prostate cancer	2.86e-05	0.000188	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CCND1—prostate cancer	2.86e-05	0.000188	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—ERBB2—prostate cancer	2.83e-05	0.000186	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	2.83e-05	0.000186	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IGF1—prostate cancer	2.83e-05	0.000186	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—EGFR—prostate cancer	2.81e-05	0.000185	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	2.8e-05	0.000184	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—MMP9—prostate cancer	2.77e-05	0.000182	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	2.76e-05	0.000181	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PTEN—prostate cancer	2.76e-05	0.000181	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	2.73e-05	0.000179	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	2.71e-05	0.000178	CbGpPWpGaD
Remifentanil—OPRD1—Signaling by GPCR—AKT1—prostate cancer	2.69e-05	0.000177	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CXCL8—prostate cancer	2.69e-05	0.000177	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.69e-05	0.000176	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	2.68e-05	0.000176	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—KRAS—prostate cancer	2.66e-05	0.000174	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—EP300—prostate cancer	2.63e-05	0.000173	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	2.63e-05	0.000172	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—FGF2—prostate cancer	2.6e-05	0.000171	CbGpPWpGaD
Remifentanil—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	2.6e-05	0.000171	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CASP3—prostate cancer	2.57e-05	0.000169	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IL2—prostate cancer	2.57e-05	0.000169	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—NOS3—prostate cancer	2.56e-05	0.000168	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—SRC—prostate cancer	2.56e-05	0.000168	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—IL6—prostate cancer	2.56e-05	0.000168	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CCND1—prostate cancer	2.5e-05	0.000164	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—VEGFA—prostate cancer	2.49e-05	0.000164	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—JAK2—prostate cancer	2.49e-05	0.000163	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	2.48e-05	0.000163	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—STAT3—prostate cancer	2.47e-05	0.000162	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.44e-05	0.00016	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—MMP9—prostate cancer	2.43e-05	0.00016	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—MDM2—prostate cancer	2.43e-05	0.00016	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	2.42e-05	0.000159	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PTEN—prostate cancer	2.42e-05	0.000159	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—ERBB2—prostate cancer	2.4e-05	0.000157	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	2.36e-05	0.000155	CbGpPWpGaD
Remifentanil—OPRK1—Signaling by GPCR—AKT1—prostate cancer	2.36e-05	0.000155	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—EP300—prostate cancer	2.31e-05	0.000151	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—MYC—prostate cancer	2.29e-05	0.00015	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—TGFB1—prostate cancer	2.29e-05	0.00015	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CXCL8—prostate cancer	2.27e-05	0.000149	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—SRC—prostate cancer	2.24e-05	0.000147	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—EGFR—prostate cancer	2.24e-05	0.000147	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	2.22e-05	0.000146	CbGpPWpGaD
Remifentanil—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	2.19e-05	0.000144	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—VEGFA—prostate cancer	2.18e-05	0.000143	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CASP3—prostate cancer	2.17e-05	0.000143	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IL2—prostate cancer	2.17e-05	0.000143	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—STAT3—prostate cancer	2.16e-05	0.000142	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—IL6—prostate cancer	2.16e-05	0.000142	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—KRAS—prostate cancer	2.12e-05	0.000139	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CCND1—prostate cancer	2.12e-05	0.000139	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	2.1e-05	0.000138	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—MMP9—prostate cancer	2.06e-05	0.000135	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	2.05e-05	0.000134	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PTEN—prostate cancer	2.04e-05	0.000134	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—MYC—prostate cancer	2.01e-05	0.000132	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—TGFB1—prostate cancer	2e-05	0.000132	CbGpPWpGaD
Remifentanil—OPRM1—Signaling by GPCR—AKT1—prostate cancer	1.99e-05	0.000131	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—EGFR—prostate cancer	1.96e-05	0.000129	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—EP300—prostate cancer	1.95e-05	0.000128	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	1.94e-05	0.000128	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—SRC—prostate cancer	1.89e-05	0.000124	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—TP53—prostate cancer	1.88e-05	0.000124	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—KRAS—prostate cancer	1.86e-05	0.000122	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—VEGFA—prostate cancer	1.85e-05	0.000121	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—STAT3—prostate cancer	1.83e-05	0.00012	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—IL6—prostate cancer	1.72e-05	0.000113	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	1.71e-05	0.000112	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—MYC—prostate cancer	1.7e-05	0.000112	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TGFB1—prostate cancer	1.69e-05	0.000111	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—EGFR—prostate cancer	1.66e-05	0.000109	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—TP53—prostate cancer	1.65e-05	0.000108	CbGpPWpGaD
Remifentanil—OPRD1—Signaling Pathways—AKT1—prostate cancer	1.59e-05	0.000104	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—KRAS—prostate cancer	1.57e-05	0.000103	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—IL6—prostate cancer	1.51e-05	9.92e-05	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	1.44e-05	9.47e-05	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—TP53—prostate cancer	1.39e-05	9.16e-05	CbGpPWpGaD
Remifentanil—OPRK1—Signaling Pathways—AKT1—prostate cancer	1.39e-05	9.15e-05	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—IL6—prostate cancer	1.28e-05	8.38e-05	CbGpPWpGaD
Remifentanil—OPRM1—Signaling Pathways—AKT1—prostate cancer	1.18e-05	7.73e-05	CbGpPWpGaD
